Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders

Am J Hematol. 2014 Mar;89(3):346-7. doi: 10.1002/ajh.23646.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Chromosome Breakpoints*
  • Chromosomes, Human, Pair 15 / genetics*
  • Chromosomes, Human, Pair 15 / ultrastructure
  • Chromosomes, Human, Pair 17 / genetics*
  • Chromosomes, Human, Pair 17 / ultrastructure
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute / etiology
  • Leukemia, Promyelocytic, Acute / genetics*
  • Male
  • Middle Aged
  • Mitoxantrone / adverse effects
  • Mitoxantrone / therapeutic use
  • Multiple Sclerosis / drug therapy
  • Neoplasms / drug therapy
  • Neoplasms, Second Primary / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Protein Isoforms / genetics
  • Topoisomerase II Inhibitors / adverse effects
  • Topoisomerase II Inhibitors / therapeutic use
  • Translocation, Genetic / genetics*

Substances

  • Antineoplastic Agents
  • Oncogene Proteins, Fusion
  • Protein Isoforms
  • Topoisomerase II Inhibitors
  • promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • Mitoxantrone